Trial Profile
A Randomized Clinical Trial to Assess the Effects of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs MK 2637 (Primary) ; Dextromethorphan
- Indications Schizophrenia
- Focus Biomarker; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 24 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Jul 2009 New trial record